StockDrifts LogoStockDrifts

Seoul Pharmaceutical 018680

Company
서울제약Seoul Pharmaceutical
Insiders
1
Buys
1
Total Value
₩23M ($16K)
Avg Return
+5.39%
Last Filing
2026-03-26

Seoul Pharmaceutical (018680) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩23M ($16K) in reported transaction value. The earliest filing StockDrifts holds for Seoul Pharmaceutical is dated 2026-03-26; the most recent is 2026-03-26. Across these filings the average return since disclosure is +5.39%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-03-26BUYMarket Buy
신봉환
Shin Bong-hwan
CEO8.3K₩2,785+5.4%₩23M ($16K)

Frequently asked questions

Who has been buying Seoul Pharmaceutical stock?
1 distinct insiders have filed 1 disclosed insider purchases in Seoul Pharmaceutical (018680), most recently on 2026-03-26. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Seoul Pharmaceutical have?
Seoul Pharmaceutical has 1 buy-side and 0 sell-side disclosures on record, covering ₩23M ($16K) in total reported value, spanning 2026-03-26 to 2026-03-26.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.